Intraocular drug delivery and filter device and methods of using same

Patent metadata

Field	Value
Publication number	US-11160908-B2
Application number	US-201916705989-A
Country	US
Kind code	B2
Filing date	Dec 6, 2019
Priority date	Sep 6, 2013
Publication date	Nov 2, 2021
Grant date	Nov 2, 2021

Abstract

The present disclosure provides an implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof.

First claim

The invention claimed is:

1. A method of treating an ocular disorder in a subject, the method comprising the steps of:
implanting into an eye of the subject, and in contact with a fluid of the eye, a device comprising a substrate having a high affinity for a target molecule present in the eye;
the substrate capturing the target molecule from the fluid;
leaving the device in the eye for a period of time to reduce or alleviate one or more symptoms of the ocular disorder; and
regenerating the device in situ by exposing the device to an energy source sufficient to denature and release a captured amount of the target molecule, wherein the device has a higher affinity for the target molecule compared to a corresponding denatured target molecule.

2. The method of claim 1 , wherein the substrate comprises a hollow tube.

3. The method of claim 2 , wherein the substrate comprises a plurality of hollow tubes bundled together.

4. The method of claim 1 , wherein the substrate is a solid, a porous matrix, a gel, a sheet, a membrane, a colloid, a microparticle, or a nanoparticle.

5. The method of claim 1 , wherein the substrate is incorporated into one of a glaucoma drainage device, an aqueous shunting device, an intraocular lens, and a drug delivery device.

6. The method of claim 1 , further comprising the steps of anchoring the device to a tissue of the eye.

7. The method of claim 1 , further comprising the steps of securing the substrate in one of an anterior chamber and a vitreous cavity of the eye.

8. The method of claim 1 , wherein the period of time is at least 6 months.

9. The method of claim 1 , further comprising the step of regenerating the device in situ at least twice.

10. The method of claim 1 , further comprising the step of regenerating the device in situ at least 4 times.

11. The method of claim 1 , wherein the device is coated with an antibody specific to the target molecule.

12. The method of claim 1 , wherein the substrate is treated with a chemical moiety such that the amount of the target molecule adsorbed to the surface is visible by color change.

13. The method of claim 1 , wherein the substrate does not include a polyethylene glycol-conjugated oligonucleotide.

Assignees

• Univ Colorado Regents

Inventors

• Olson Jeffrey

Classifications

• A61K9/0051 Primary

  Ocular inserts or implants · CPC title

• A61F9/0017

  implantable in, or in contact with, the eye, e.g. ocular inserts · CPC title

• A61L2300/112

  Phosphorus-containing compounds, e.g. phosphates, phosphonates · CPC title

• A61L31/026 Primary

  Ceramic or ceramic-like structures, e.g. glasses · CPC title

• A61F9/00802

  for photoablation · CPC title